Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02134028
Recruitment Status : Completed
First Posted : May 8, 2014
Last Update Posted : October 17, 2019
Regeneron Pharmaceuticals
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 11, 2019
Actual Study Completion Date : October 11, 2019